Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03003 MAD Study in Early-Stage Parkinson's Disease
NCT04045678Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Oct 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing LY03003 with Placebo (2 arms). Primary endpoint: Frequency of adverse events. Started Oct 2017; status: completed.
02
Drugs
Rotigotine extended-release microspheres
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04045678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04045678.